Recombinant interferon beta (IFNβ) is a first-line therapy for relapsing-remitting multiple sclerosis (MS) and its therapeutic effect includes reduced frequency of clinical relapses and new lesions [1], [2] and reduced accumulation of disability over time [3]. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.